Click here for Analysts' Upgrades, Downgrades.
Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
STOCK COMMENTS / EPS CHANGES
Arch Capital Group
price target boosted at Barclays. ACGL price target raised to $105 from $90. Company has strong management team, and can generate top-tier performance, Barclays said. Maintain Overweight rating.
price target increased at BofA/Merrill. ANN price target lifted to $30 from $28 on strong momentum and Loft is improving, Bank of America/Merrill Lynch said. Maintain Buy rating.
numbers upped at UBS. ANN estimates were boosted through 2012. Margins are improving, along with fundamentals. Buy rating and new $32 price target.
numbers boosted at Keybanc. Shares o f APD now seen reaching $105, according to Keybanc. Estimates were also upped, given the company's cyclical leverage. Buy rating.
estimates cut at Goldman. BAX estimates were lowered through 2013, Goldman Sachs said. Company is facing a higher tax rate. Buy rating and $58 price target.
price target increased at Barclays. BBY price target lifted to $51 from $49 as Barclays is expecting strong performance from BBY this holiday season. Maintain Overweight rating.
price target boosted at Barclays. CAT price target lifted to $87 from $85. The BUCY acquisitions - bullish on the mining cycle and the attractive synergies on the way, Barclays said. Maintain Equal Weight rating.
estimates, target increased at Citigroup. CMI estimates were raised through 2011, Citigroup said. Company can leverage its growth in the emerging markets. Buy rating and new $110 price target.
price target raised at BofA/Merrill. CVC price target increased to $37 from $34 as the proposed Rainbow spin will be positive for shares, Bank of America/Merrill Lynch said. Maintain Buy rating.
numbers raised at UBS. Shares of ESRX now seen reaching $66. Estimates also increased, given higher growth in the mailing business. Buy rating.
target boosted at FBR. Shares of FL now seen reaching $21. Company is improving its merchandising. Outperform rating.
price target trimmed at Barclays. HNT price target reduced by a dollar to $29 as the Centers for Medicare & Medicaid Services announced sanctions against HNT. Maintain Underweight rating.
target raised at FBR. Shares of HON now seen reaching $57. Company can generate organic growth in aerospace. Market Perform rating.
estimates lowered at Goldman through 2011. Company cut guidance, because of fewer Medicare payments. Neutral rating and $57 price target.
price target boosted at Barclays to $74 from $68. With the CCE transaction closed and still more than $13 billion in cash on the balance sheet, shareholders should expect more buybacks and dividends, Barclays said. Maintain Overweight rating.
target increased at UBS to $76. Company is positioned well for generic growth. Buy rating.
estimates cut at Goldman through 2013. Company likely to see lower hard-drive demand. Buy rating and $22 price target.
estimates increased at Goldman through 2012. Company is keeping a tight lid on costs. Buy rating and $55 price target.
Research in Motion
( RIMM) estimates upped at Oppenheimer through 2012. Playbook should sell well. Perform rating.
price target boosted at Barclays to $64 from $55 as Barclays is expecting strong 3Q10 results, which it will release on Wednesday. Maintain Overweight rating.
The Travelers Companies
price target raised at Barclays to $66 from $61. Stock will trade at increasingly attractive valuations and superior management team. Maintain Overweight rating.
estimates raised at Goldman. Shares of YHOO now seen reaching $19, according to Goldman Sachs. Estimates also increased, given higher expected revenue per search. Neutral rating.
This article was written by a staff member of TheStreet.